The US FDA has approved cabozantinib for treating adult and pediatric patients aged 12 years and older with well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). It is specifically indicated for patients with previously treated, unresectable, locally advanced, or metastatic pNET and epNET. Cabozantinib was previously approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Clinical evidence In clinical trials, cabozantinib significantly improved progression-free survival in patients with pNET (13.8 vs.
3.3 months; hazard Ratio [HR]: 0.22) and those with epNET (8.5 vs. 4.2 months; HR: 0.40) compared to a placebo. Dosage and administration Available as tablet Administer on an empty stomach at least one hour before or two hours after eating Stop the treatment at least three weeks before…
